Courtney Breen

“Lily, team, thanks so much for taking the question today. I did just want to probe on the Red or True Tide regulatory pathway.”

“Martine, thanks so much for the question today. Just one on Lephendra, following up on the comments regarding kind of fixed-ose combinations.”

“I really wanted to just understand a little bit more about the HIV treatment strength, specifically kind of looking at Bictalvi. we saw performance beyond consensus expectations, and this is in the context of insurance coverage losses in the U.S., and so wanting to get your context around how we should think about the…”

“Just a couple of others want to push a little bit further on norovirus and the update there. Obviously the question that I think many of us are asking is, is this enrollment, is this an efficacy or is this an events situation?”

“I just wanted to ask a little bit about aloralentide. You kind of highlighted it in the slides and emphasized the perhaps more biased binding that you have with euramilin compared to others.”